Latham acts for Baxter on latest pharma acquisition as HSF picks up new client Claris

Herbert Smith Freehills (HSF) and Latham & Watkins won lead roles on Baxter International’s acquisition of Claris Injectables for $625m, in a bid by Baxter to expand its portfolio of essential generic injectable medicines. HSF represented Claris, while Latham acted for Baxter.

Continue reading “Latham acts for Baxter on latest pharma acquisition as HSF picks up new client Claris”

Comment: After shocks of 2016, law leaders may need to start thinking

Well, it is nearly over and few in the profession will mourn the passing of 2016. Not since the banking crisis of 2008/09 have 12 months so drastically recast the environment in which law firms ply their trade, most strikingly, of course, in June’s vote for Britain to quit the EU and November’s election of Donald Trump as the 45th US president. Continue reading “Comment: After shocks of 2016, law leaders may need to start thinking”